J. I. Harwell, T. P. Flanigan, and J. A. Mitty, Directly observed antiretroviral therapy to reduce genital tract and plasma HIV-1

, RNA in women with poor adherence, Aids, vol.17, pp.1990-1993, 2003.

P. Roux, C. Lions, and J. Cohen, Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13HEPAVIH cohort, Antivir Ther, vol.19, pp.171-178, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-00903463

A. Ammassari, A. Antinori, and M. S. Aloisi, Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons, Psychosomatics, vol.45, pp.394-402, 2004.

A. D. Bouhnik, M. Preau, and E. Vincent, Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy, Antivir Ther, vol.10, pp.53-61, 2005.
URL : https://hal.archives-ouvertes.fr/halshs-01563649

B. W. Pence, W. C. Miller, B. N. Gaynes, and J. J. Eron, Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy, J Acquir Immune Defic Syndr, vol.44, pp.159-166, 2007.

V. Villes, B. Spire, and C. Lewden, The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice, Antivir Ther, vol.12, pp.1067-1074, 2007.

F. Marcellin, M. Preau, I. Ravaux, P. Dellamonica, B. Spire et al., Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research, HIV Clin Trials, vol.8, pp.320-327, 2007.

L. Michel, V. Villes, and F. Dabis, Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, J Viral Hepat, vol.17, issue.9, pp.650-660, 2006.

M. Preau, F. Marcellin, and B. Spire, Impaired anger control as an underappreciated side effect of treatments for chronic HCV infection in HIV-HCV coinfected patients, J Clin Gastroenterol, vol.42, pp.92-96, 2008.
URL : https://hal.archives-ouvertes.fr/halshs-01563621

E. Dieperink, M. Willenbring, and S. B. Ho, Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review, Am J Psychiatry, vol.157, pp.867-876, 2000.

C. Henry, L. Castera, and J. Demotes-mainard, Hepatitis C and interferon: Watch for hostility, impulsivity, Current Psychiatry, vol.5, pp.71-78, 2006.

M. Schaefer, F. Schmidt, and C. Folwaczny, Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups, Hepatology, vol.37, pp.443-451, 2003.

M. A. Loko, D. Salmon, and P. Carrieri, The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, BMC Infect Dis, vol.10, p.303, 2006.
URL : https://hal.archives-ouvertes.fr/pasteur-01070193

D. V. Sheehan, Y. Lecrubier, and K. H. Sheehan, The MiniInternational Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J Clin Psychiatry, vol.59, pp.4-57, 1998.

M. Schaefer, R. Sarkar, and C. Diez-quevedo, Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction, Clin Infect Dis, vol.57, issue.2, pp.111-117, 2013.

S. Sockalingam and S. E. Abbey, Managing depression during hepatitis C treatment, Can J Psychiatry, vol.54, pp.614-625, 2009.

B. Gohier, J. L. Goeb, K. Rannou-dubas, I. Fouchard, P. Cales et al., Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients
URL : https://hal.archives-ouvertes.fr/hal-00346673

, World J Biol Psychiatry, vol.4, pp.115-118, 2003.

H. Rifflet, E. Vuillemin, and F. Oberti,

, Gastroenterol Clin Biol, vol.22, pp.353-357, 1998.

J. M. Loftis and P. Hauser, The phenomenology and treatment of interferon-induced depression, J Affect Disord, vol.82, pp.175-190, 2004.

T. Nickel, A. Sonntag, M. Backmund, and T. Pollmacher, Depression during therapy with interferon alpha-how long should an antidepressant treatment last?, Pharmacopsychiatry, vol.38, pp.102-104, 2005.

K. Koseki, M. Nakano, M. Takaiwa, T. Kamata, and J. Yosida, Suicidal attempts in three postoperative patients with renal cancer after alpha interferon withdrawal, Nihon Hinyokika Gakkai Zasshi, vol.91, pp.29-32, 2000.

J. P. Lang, O. Halleguen, V. Vecchionacci, and M. Doffoel, Reflections on the treatment of EDM in hepatitis C virus patients treated with interferon alpha from a retrospective survey concerning 29 patients, Encephale, vol.29, pp.273-277, 2003.

M. Schaefer, L. Capuron, and A. Friebe, Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement, J Hepatol, vol.57, pp.1379-1390, 2012.

M. Schaefer, A. Hinzpeter, and A. Mohmand, Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects, Hepatology, vol.46, pp.991-998, 2007.

B. Zanini, L. Covolo, F. Donato, and A. Lanzini, Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies

, Clin Ther, vol.32, pp.2139-2159, 2010.

I. Zeiler, T. Langlands, J. M. Murray, and A. Ritter, Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs, Drug Alcohol Depend, vol.110, pp.228-233, 2010.

, The burden of depression, Nature, vol.515, p.163, 2014.

D. J. Smith, H. Court, and G. Mclean, Depression and multimorbidity: a cross-sectional study of 1,751,841 patients in primary care, J Clin Psychiatry, vol.75, pp.1202-1208, 2014.